Genetico has received a patent for Onconetix, its system for the genetic analysis of neoplasms for the personalization of antitumor therapy. The technology, based on the new generation sequencing (NGS) method, provides the analysis of somatic mutations in tumor tissues, allowing oncologists to develop treatment regimens based on the genetic characteristics of each patient’s neoplasms.
According to the International Agency for Research on Cancer, there were almost 20 million new cases of cancer and close to 10 million deaths from cancer in 2022. The annual number of new cases of cancer is predicted to reach 35 million by 2050, that is, a 77% increase from the number in 2022.
In Russia, NGS studies are partially covered by compulsory health insurance program, while comprehensive genetic diagnostics is provided on a self-pay basis. The Onconetix panel is available in the Genetico laboratory and partner clinics. In October 2023, a new branch of the Genetico center with an oncologist’s office opened in the Medtech Moscow Technopark.
